---
title: "Integra LifeSciences | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 382.65 M"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/238787815.md"
datetime: "2025-05-05T20:10:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238787815.md)
  - [en](https://longbridge.com/en/news/238787815.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238787815.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/238787815.md) | [English](https://longbridge.com/en/news/238787815.md)


# Integra LifeSciences | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 382.65 M

Revenue: As of FY2025 Q1, the actual value is USD 382.65 M, beating the estimate of USD 381.17 M.

EPS: As of FY2025 Q1, the actual value is USD -0.33, missing the estimate of USD -0.005.

EBIT: As of FY2025 Q1, the actual value is USD -15.5 M.

### Codman Specialty Surgical Segment

-   **Revenue**: $280.7 million for the three months ended March 31, 2025, an increase of $24.2 million compared to the prior-year period, inclusive of $29.1 million related to the Acclarent acquisition.
-   **Cost of Goods Sold**: $92.7 million for the three months ended March 31, 2025.
-   **Operating Income**: $110.4 million for the three months ended March 31, 2025.

### Tissue Technologies Segment

-   **Revenue**: $102.0 million for the three months ended March 31, 2025, a decrease of $10.4 million compared to the prior-year period.
-   **Cost of Goods Sold**: $45.1 million for the three months ended March 31, 2025.
-   **Operating Income**: $16.0 million for the three months ended March 31, 2025.

### Corporate and Other

-   **Operating Loss**: - $141.9 million for the three months ended March 31, 2025.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $11.3 million for the three months ended March 31, 2025.
-   **Net Cash Used in Investing Activities**: - $35.9 million for the three months ended March 31, 2025.
-   **Net Cash Provided by Financing Activities**: $35.4 million for the three months ended March 31, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is focused on innovating for outcomes, growing internationally, and broadening impact on care pathways. Key priorities include obtaining PMA approval for SurgiMend and DuraSorb, expanding the urinary bladder matrix platform, and enhancing the quality management system.
-   **Non-Core Business**: The company is implementing the Compliance Master Plan to improve quality management systems and transferring manufacturing from the Boston facility to the Braintree facility.

### Strategic Initiatives

-   **Operational Excellence**: Investments in capacity expansion and quality management system improvements are ongoing, including the transition of manufacturing activities to the Braintree facility.

### 相關股票

- [Integra LifeSciences (IART.US)](https://longbridge.com/zh-HK/quote/IART.US.md)

## 相關資訊與研究

- [BUZZ-Integra falls on downbeat first-quarter profit outlook](https://longbridge.com/zh-HK/news/277081990.md)
- [Integra LifeSciences Earnings Call: Mixed Sentiment and Strategic Advancements](https://longbridge.com/zh-HK/news/263817350.md)
- [Integra LifeSciences Reports Q4 Loss, Revenue Edges Down](https://longbridge.com/zh-HK/news/277030937.md)
- [FDA Issues Alert For Integra Wound Care Products Over Infection Fears](https://longbridge.com/zh-HK/news/273543037.md)
- [FDA Says Integra Lifesciences Identified Packaging Failures Related To Medihoney Wound & Burn Products & CVS Wound Gel Products](https://longbridge.com/zh-HK/news/273412120.md)